Bicara Therapeutics (NASDAQ:BCAX) Posts Earnings Results, Misses Estimates By $0.08 EPS

Bicara Therapeutics (NASDAQ:BCAX) issued its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08), Zacks reports.

Bicara Therapeutics Price Performance

BCAX stock traded up $0.02 on Friday, reaching $13.42. 58,204 shares of the company’s stock were exchanged, compared to its average volume of 457,303. The company has a fifty day moving average of $13.01. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright lifted their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.